Novel Cancer Drugs Based on Epigenetics, miRNAs and their Interactions

Abstract

EpigenomicsVol. 3, No. 6 EditorialNovel cancer drugs based on epigenetics, miRNAs and their interactionsDimitrios H RoukosDimitrios H RoukosPersonalized Cancer Genomic Medicine, Ioannina University, Ioannina, TK 451 10, Greece and Department of Surgery, Ioannina University School of Medicine, Ioannina, TK 451 10, Greece. Search for more papers by this authorEmail the corresponding author at droukos@uoi.grPublished Online:25 Nov 2011https://doi.org/10.2217/epi.11.91AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biomarkersepigeneticsfunctional genomicsmiRNAsnetworkssequencingsolid tumorsReferences1 Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol.28,1057–1068 (2010).Crossref, Medline, CAS, Google Scholar2 Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol.28(10),1069–1078 (2010).Crossref, Medline, CAS, Google Scholar3 Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat. Res. doi:10.1016/j.mrfmmm.2011.03.009 (2011) (Epub ahead of print).Medline, Google Scholar4 Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov.9(10),775–789 (2010).Crossref, Medline, CAS, Google Scholar5 Green ED, Guyer MS; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature470(7333),204–213 (2011).Crossref, Medline, CAS, Google Scholar6 Dulbecco R. A turning point in cancer research: sequencing the human genome. Science231,1055–1056 (1986).Crossref, Medline, CAS, Google Scholar7 Lander ES, Linton LM, Birren B et al.; International Human Genome Sequencing Consortium: initial sequencing and analysis of the human genome. Nature409,860–921 (2001).Crossref, Medline, CAS, Google Scholar8 Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science291,1304–1351 (2001).Crossref, Medline, CAS, Google Scholar9 Marshall E. Human genome 10th anniversary. Waiting for the revolution. Science331(6017),526–529 (2011).Crossref, Medline, CAS, Google Scholar10 Wadman M. Fifty genome sequences reveal breast cancer’s complexity. Nature doi:10.1038/news.2011.203 (2011) (Epub ahead of print).Google Scholar11 Blaxter M. Genetics. Revealing the dark matter of the genome. Science330(6012),1758–1759 (2010).Crossref, Medline, CAS, Google Scholar12 Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell145(1),30–38 (2011).Crossref, Medline, CAS, Google Scholar13 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5),646–674 (2011).Crossref, Medline, CAS, Google Scholar14 Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell145(1),19–24 (2011).Crossref, Medline, CAS, Google Scholar15 Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol.7(12),668–680 (2010).Crossref, Medline, CAS, Google Scholar16 Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature429,457–463 (2004).Crossref, Medline, CAS, Google Scholar17 Chi P, Allis CD, Wang GG. Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer10(7),457–469 (2010).Crossref, Medline, CAS, Google Scholar18 Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis31,27–36 (2010).Crossref, Medline, CAS, Google Scholar19 Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol.27,5459–5468 (2009).Crossref, Medline, CAS, Google Scholar20 Belinsky SA, Grimes MJ, Picchi MA, et al. Combination therapy with Vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res.71(2),454–462 (2011).Crossref, Medline, CAS, Google Scholar21 Kaiser J. Epigenetic drugs take on cancer. Science330(6004),576–578 (2010).Crossref, Medline, CAS, Google Scholar22 Munker R, Calin GA. MicroRNA profiling in cancer. Clin. Sci. (Lond).121(4),141–158 (2011).Crossref, Medline, CAS, Google Scholar23 Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature476(7360),298–303 (2011).Crossref, Medline, CAS, Google Scholar24 Beltrao P, Cagney G, Krogan N. Quantitative genetic interactions reveal biological modularity. Cell141(5),739–745 (2010).Crossref, Medline, CAS, Google Scholar25 Davis DA, Chawla NV. Exploring and exploiting disease interactions from multi-relational gene and phenotype networks. PLoS ONE6(7),e22670 (2011).Crossref, Medline, CAS, Google Scholar101 miRBase. www.mirbase.orgGoogle ScholarFiguresReferencesRelatedDetailsCited ByEpigenetics and animal models: applications in cancer control and treatmentCancer-Associated Infectious Agents and Epigenetic Regulation8 November 2014Epigenetics and Animal Models Vol. 3, No. 6 Follow us on social media for the latest updates Metrics Downloaded 546 times History Published online 25 November 2011 Published in print December 2011 Information© Future Medicine LtdKeywordsbiomarkersepigeneticsfunctional genomicsmiRNAsnetworkssequencingsolid tumorsFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download